

FDA grants orphan status for Halo's DMD drug candidate

Mass High Tech: The Journal of New England Technology

Halo Therapeutics LLC, a Newton biotech founded through a unique do-it-yourself drug development process, has won orphan drug designation from the U.S. Food and Drug Administration for HT-100, its treatment for Duchenne muscular dystrophy (DMD).

[SOURCE](#) [1]

Source URL (retrieved on 02/01/2015 - 1:21pm):

http://www.mdtmag.com/news/2012/01/fda-grants-orphan-status-halos-dmd-drug-candidate?qt-video_of_the_day=0

Links:

[1] <http://www.masshightech.com/stories/2012/01/02/daily18-FDA-grants-orphan-status-for-Halos-DMD-drug-candidate.html>